Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Major Diseases in the Population, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin 300060, China.
Department of Biochemistry and Molecular Biology, Tianjin Key Laboratory of Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Phytomedicine. 2024 Oct;133:155950. doi: 10.1016/j.phymed.2024.155950. Epub 2024 Aug 10.
Dietary flavonoids may have potential effects on hormone-related cancers (HRCs) due to their anti-cancer properties via regulating hormones and suppressing inflammation and oxidative stress. We aimed to examine the association of flavonoid intake with risks of HRCs and whether this association was mediated by blood biomarkers involved in biological mechanisms.
This prospective cohort study from UK Biobank included 187,350 participants free of cancer when the last dietary recall was completed. The dietary intakes of flavonoids and subclasses were assessed using 24-hour dietary recalls. Venous blood was collected at baseline and assayed for biomarkers of inflammation, hormones, and oxidative stress. Hazard ratios (HR) and 95 % confidential intervals (CI) for the associations between flavonoid intake and HRCs risk were estimated by the cause-specific Cox proportional hazards model. The role of blood biomarkers in the flavonoids-HRCs association was investigated through mediation analysis.
Over a median follow-up of 9.5 years, 3,392 female breast cancer, 417 ovarian cancer, 516 endometrial cancer, 4,305 prostate cancer, 45 testicular cancer, and 146 thyroid cancer cases were documented. Compared to the lowest quintile, multivariable-adjusted HRs (95 % CIs) in the highest quintile of total flavonoid intake were 0.89 (0.80-0.99) for breast cancer, 0.68 (0.50-0.92) for ovarian cancer, and 0.88 (0.80-0.98) for female-specific cancers. For subclasses, intakes of flavonols and anthocyanidins were inversely associated with the risk of female-specific cancers (P <0.05). Anthocyanidin intake was positively related to prostate cancer risk, whereas isoflavone intake was inversely linked to thyroid cancer risk (P <0.05). Additionally, certain biomarkers of inflammation, hormones and oxidative stress jointly mediated the association of flavonoid intake with the risk of female-specific cancers and prostate cancer.
Our findings highlighted the importance of dietary flavonoids for the prevention of HRCs in the general population, providing epidemiological evidence for dietary guidelines.
由于黄酮类化合物具有抗癌特性,可通过调节激素、抑制炎症和氧化应激来发挥作用,因此它们可能对与激素相关的癌症(HRC)具有潜在影响。我们旨在研究黄酮类化合物的摄入量与 HRC 风险之间的关联,以及这种关联是否通过参与生物学机制的血液生物标志物来介导。
这项来自英国生物库的前瞻性队列研究纳入了 187350 名在最后一次饮食回顾完成时无癌症的参与者。使用 24 小时饮食回忆法评估黄酮类化合物和亚类的饮食摄入量。在基线时采集静脉血,并检测炎症、激素和氧化应激的生物标志物。使用特定病因的 Cox 比例风险模型估计黄酮类化合物摄入量与 HRC 风险之间的关联的风险比(HR)和 95%置信区间(CI)。通过中介分析研究血液生物标志物在黄酮类化合物-HRCs 关联中的作用。
在中位数为 9.5 年的随访期间,共记录了 3392 例女性乳腺癌、417 例卵巢癌、516 例子宫内膜癌、4305 例前列腺癌、45 例睾丸癌和 146 例甲状腺癌病例。与最低五分位数相比,总黄酮摄入量最高五分位数的多变量校正 HR(95%CI)分别为乳腺癌 0.89(0.80-0.99)、卵巢癌 0.68(0.50-0.92)和女性特异性癌症 0.88(0.80-0.98)。对于亚类,类黄酮和花色苷的摄入量与女性特异性癌症的风险呈负相关(P<0.05)。花色苷的摄入量与前列腺癌的风险呈正相关,而异黄酮的摄入量与甲状腺癌的风险呈负相关(P<0.05)。此外,某些炎症、激素和氧化应激的生物标志物共同介导了黄酮类化合物的摄入量与女性特异性癌症和前列腺癌风险之间的关联。
我们的研究结果强调了饮食中黄酮类化合物对预防一般人群中 HRC 的重要性,为饮食指南提供了流行病学证据。